Skip to main content

11-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: Better outcomes in relapsing MS patients switching to natalizumb versus fingolimod after first-line treatment

Tim Spelman discusses his team’s findings of a significant reduction in relapse rates and greater disability improvement in multiple sclerosis patients who relapse on first-line treatment and switch to natalizumab versus fingolimod (2:55).

Funding for this video was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits